Related Experiment Video
Updated: Feb 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
A two-drug combination simulation study for metastatic castrate resistant prostate cancer
Alex Root1, H Alexander Ebhardt2
1Molecular Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Background:
Prostate cancer often evolves resistance to androgen deprivation therapy leading to a lethal metastatic castrate-resistant form. Besides androgen independence, subpopulations of the tumor are genetically heterogeneous. With the advent of tumor genome sequencing we asked which has the greater influence on reducing tumor size: genetic background, heterogeneity, or drug potency?
Methods:
A previously developed theoretical evolutionary dynamics model of stochastic branching processes is applied to compute the probability of tumor eradication with two targeted drugs. Publicly available data sets were surveyed to parameterize the model.
Results:
Our calculations reveal that the greatest influence on successful treatment is the genetic background including the number of mutations overcoming resistance. Another important criteria is the tumor size at which it is still possible to achieve tumor eradication, for example, 2-4 cm large tumors have at best a 10% probability to be eradicated when 50 mutations can confer resistance to each drug.
Conclusion:
Overall, this study finds that genetic background and tumor heterogeneity are more important than drug potency in treating mCRPC. It also points toward identifying metastatic sites early using biochemical assays and/or dPET.
Insights
Genetic background and tumor heterogeneity significantly impact prostate cancer treatment success more than drug potency. Early detection of metastatic sites is crucial for improving outcomes in metastatic castrate-resistant prostate cancer (mCRPC).
Area of Science:
- Oncology
- Evolutionary Biology
- Computational Biology
Background:
- Prostate cancer frequently develops resistance to androgen deprivation therapy, progressing to metastatic castrate-resistant prostate cancer (mCRPC).
- Tumor subpopulations exhibit genetic heterogeneity alongside androgen independence.
- The relative impact of genetic factors versus drug efficacy on tumor reduction is investigated.
Purpose of the Study:
- To determine whether genetic background, tumor heterogeneity, or drug potency has a greater influence on reducing prostate tumor size.
- To model the probability of tumor eradication using targeted therapies.
Main Methods:
- Application of a theoretical evolutionary dynamics model based on stochastic branching processes.
- Parameterization of the model using publicly available datasets.
- Computation of tumor eradication probabilities for two targeted drugs.
Main Results:
- Genetic background, including the number of resistance-conferring mutations, is the primary factor influencing treatment success.
- Tumor size is a critical determinant; larger tumors (e.g., 2-4 cm) have a low eradication probability (≤10%) if 50 mutations confer resistance.
- Drug potency is less influential compared to genetic factors.
Conclusions:
- Genetic background and tumor heterogeneity are more critical than drug potency in treating mCRPC.
- Early identification of metastatic sites using assays like dPET is recommended.
- Understanding the evolutionary dynamics of prostate cancer is key to developing effective therapeutic strategies.
Related Concept Videos
Treatment Resistant Cancers
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Resistivity
Resistance

